Nivolumab Combined with Ibrutinib for Relapsed, Refractory or High-risk Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
The goal of this clinical research study is to learn if nivolumab in combination with ibrutinib can help control chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), or small lymphocytic leukemia (SLL). The safety of this drug combination will also be studied.
Treatment Location: N/A
IRB Review and Approval Date: 06/19/2015
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: